Pharmaceutical company Mayne Pharma
(ASX:MYX) reported financial year 2018 revenue of $530 million, adjusted EBITDA of $165 million and reported a net loss after tax of $134 million.
These full year results were impacted by a number of one-off items including non-cash intangible asset impairment, stock becoming obselete, abnormal antibiotic Doryx returns and a charge to income tax expense resulting from the US corporate federal tax rate change.
The Company ended the year with cash of $87 million and outstanding borrowings of $374 million.
Shares in Mayne Pharma
(ASX:MYX) 0.85 per cent lower at $1.17.
